Literature DB >> 20844034

Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions.

François Helle1, Gabrielle Vieyres, Laure Elkrief, Costin-Ioan Popescu, Czeslaw Wychowski, Véronique Descamps, Sandrine Castelain, Philippe Roingeard, Gilles Duverlie, Jean Dubuisson.   

Abstract

Hepatitis C virus (HCV) envelope glycoproteins are highly glycosylated, with generally 4 and 11 N-linked glycans on E1 and E2, respectively. Studies using mutated recombinant HCV envelope glycoproteins incorporated into retroviral pseudoparticles (HCVpp) suggest that some glycans play a role in protein folding, virus entry, and protection against neutralization. The development of a cell culture system producing infectious particles (HCVcc) in hepatoma cells provides an opportunity to characterize the role of these glycans in the context of authentic infectious virions. Here, we used HCVcc in which point mutations were engineered at N-linked glycosylation sites to determine the role of these glycans in the functions of HCV envelope proteins. The mutants were characterized for their effects on virus replication and envelope protein expression as well as on viral particle secretion, infectivity, and sensitivity to neutralizing antibodies. Our results indicate that several glycans play an important role in HCVcc assembly and/or infectivity. Furthermore, our data demonstrate that at least five glycans on E2 (denoted E2N1, E2N2, E2N4, E2N6, and E2N11) strongly reduce the sensitivity of HCVcc to antibody neutralization, with four of them surrounding the CD81 binding site. Altogether, these data indicate that the glycans associated with HCV envelope glycoproteins play roles at different steps of the viral life cycle. They also highlight differences in the effects of glycosylation mutations between the HCVpp and HCVcc systems. Furthermore, these carbohydrates form a "glycan shield" at the surface of the virion, which contributes to the evasion of HCV from the humoral immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844034      PMCID: PMC2977866          DOI: 10.1128/JVI.01548-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

3.  Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses.

Authors:  J Dubuisson; H H Hsu; R C Cheung; H B Greenberg; D G Russell; C M Rice
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

4.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

Authors:  H Nakabayashi; K Taketa; K Miyano; T Yamane; J Sato
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701

5.  Carbohydrate composition of the membrane glycoprotein of vesicular stomatitis virus grown in four mammalian cell lines.

Authors:  J R Etchison; J J Holland
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

6.  Characterization of functional hepatitis C virus envelope glycoproteins.

Authors:  Anne Op De Beeck; Cécile Voisset; Birke Bartosch; Yann Ciczora; Laurence Cocquerel; Zhenyong Keck; Steven Foung; François-Loïc Cosset; Jean Dubuisson
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

7.  The antigenic structure of the HIV gp120 envelope glycoprotein.

Authors:  R Wyatt; P D Kwong; E Desjardins; R W Sweet; J Robinson; W A Hendrickson; J G Sodroski
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

8.  In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes.

Authors:  Birke Bartosch; Jens Bukh; Jean-Christophe Meunier; Christelle Granier; Ronald E Engle; William C Blackwelder; Suzanne U Emerson; François-Loïc Cosset; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

9.  Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes.

Authors:  Birke Bartosch; Jean Dubuisson; François-Loïc Cosset
Journal:  J Exp Med       Date:  2003-03-03       Impact factor: 14.307

10.  Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

Authors:  Jasminka Sterjovski; Melissa J Churchill; Anne Ellett; Lachlan R Gray; Michael J Roche; Rebecca L Dunfee; Damian F J Purcell; Nitin Saksena; Bin Wang; Secondo Sonza; Steven L Wesselingh; Ingrid Karlsson; Eva-Maria Fenyo; Dana Gabuzda; Anthony L Cunningham; Paul R Gorry
Journal:  Retrovirology       Date:  2007-12-12       Impact factor: 4.602

View more
  109 in total

1.  Hepatitis C virus epitope exposure and neutralization by antibodies is affected by time and temperature.

Authors:  Michelle C Sabo; Vincent C Luca; Stuart C Ray; Jens Bukh; Daved H Fremont; Michael S Diamond
Journal:  Virology       Date:  2011-11-12       Impact factor: 3.616

2.  Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus.

Authors:  Holly Freedman; Michael R Logan; Darren Hockman; Julia Koehler Leman; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.

Authors:  Nicholas J Lennemann; Andrew S Herbert; Rachel Brouillette; Bethany Rhein; Russell A Bakken; Katherine J Perschbacher; Ashley L Cooney; Catherine L Miller-Hunt; Patrick Ten Eyck; Julia Biggins; Gene Olinger; John M Dye; Wendy Maury
Journal:  J Virol       Date:  2017-08-10       Impact factor: 5.103

Review 4.  Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain.

Authors:  Ali Sabahi; Susan L Uprichard; William C Wimley; Srikanta Dash; Robert F Garry
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

5.  HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Authors:  Yalena Amador-Cañizares; Gillian Martínez-Donato; Liz Alvarez-Lajonchere; Claudia Vasallo; Mariacarla Dausá; Daylen Aguilar-Noriega; Carmen Valenzuela; Ivette Raíces; Jean Dubuisson; Czeslaw Wychowski; Zurina Cinza-Estévez; Marlén Castellanos; Magdalys Núñez; Anny Armas; Yaimé González; Ismariley Revé; Ivis Guerra; Angel Pérez Aguiar; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

6.  Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1.

Authors:  Ahmed Atef Mesalam; Isabelle Desombere; Ali Farhoudi; Freya Van Houtte; Lieven Verhoye; Jonathan Ball; Jean Dubuisson; Steven K H Foung; Arvind H Patel; Mats A A Persson; Geert Leroux-Roels; Philip Meuleman
Journal:  Virology       Date:  2017-11-10       Impact factor: 3.616

7.  Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth.

Authors:  Jinghe Huang; Byong H Kang; Elise Ishida; Tongqing Zhou; Trevor Griesman; Zizhang Sheng; Fan Wu; Nicole A Doria-Rose; Baoshan Zhang; Krisha McKee; Sijy O'Dell; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Chaim A Schramm; Anqi Zheng; M Gordon Joyce; Mangaiarkarasi Asokan; Amy Ransier; Sam Darko; Stephen A Migueles; Robert T Bailer; Mark K Louder; S Munir Alam; Robert Parks; Garnett Kelsoe; Tarra Von Holle; Barton F Haynes; Daniel C Douek; Vanessa Hirsch; Michael S Seaman; Lawrence Shapiro; John R Mascola; Peter D Kwong; Mark Connors
Journal:  Immunity       Date:  2016-11-15       Impact factor: 31.745

8.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Authors:  Stéphanie B N Serre; Henrik B Krarup; Jens Bukh; Judith M Gottwein
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

10.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.